Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

Introduction Insomnia is a highly prevalent and costly condition that is associated with increased health risks and healthcare utilisation. Anecdotally, cannabis use is frequently reported by consumers to promote sleep. However, there is limited research on the effects of cannabis on sleep and dayti...

Full description

Bibliographic Details
Main Authors: Brendon J Yee, Ronald R Grunstein, Christopher J Gordon, Anastasia Suraev, Nathaniel S Marshall, Angela L D'Rozario, Delwyn J Bartlett, Keith Wong, Ryan Vandrey, Chris Irwin, Jonathon C Arnold, Iain S McGregor, Camilla M Hoyos
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/5/e034421.full

Internet

https://bmjopen.bmj.com/content/10/5/e034421.full

Similar Items